Smith Sandford D
SEC-identified person · CIK 1243004 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Cytokinetics INC CYTK | Director | filed 2012 - 2024 |
| Akcea Therapeutics, INC. AKCA | Director | filed 2017 - 2020 |
| Seneca Biopharma, Inc. SNCA | Director | filed 2014 - 2019 |
| Seelos Therapeutics, INC. SEEL | Director | filed 2014 - 2018 |
| QLT INC/BC QLTI | Director | filed 2016 - 2017 |
| Aegerion Pharmaceuticals, Inc. AEGR | Director · Chief Executive Officer | filed 2012 - 2016 |
| Genzyme Corp u4yfvwk$ | Senior Vice President | filed 2006 - 2011 |
| Ariad Pharmaceuticals INC ARIA | Director | filed 2006 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.